TFX - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2019 Teleflex Incorporated Earnings Conference Call. [Operator Instructions].

I would now like to hand the conference over to your speaker today, Jake Elguicze, Treasurer and Vice President of Investor Relations. Please go ahead, sir.

Jake Elguicze

Thank you and good morning everyone, and welcome to the Teleflex Incorporated Third Quarter 2019 Earnings Conference Call. slides at this www.teleflex.com. and on are release website our press to call accompany available The

available then or and to Kelly, Liam provide will and Officer; As available XXXXXXX. Executive we'll and up President be on reminder, Participating call our dialing Thomas a and this are the open website President a call and on today's replay Liam XXX-XXX-XXXX, international calls for Chief and will Vice call be by Q&A. Tom prepared passcode XXX-XXX-XXXX Powell, Executive Chief Officer. remarks, Financial will

we you and the the materially. in fact, Before results that uncertainties begin, forward-looking as some risks I'd nature will We in or may call differ forward-looking our remind like statements in you are that wish discussed in statements future subject caution to events to and outlined such matters are, contain and events regarding of actual conference slides. to

differ actual call release The but to that today cause press XX-K, With with Liam. factors as limited that as our like accessed are I'd the now could events to well results be our our our on materially factors in which Form the including not said, website. filings include, to, referenced SEC, turn to can or over

Liam Kelly

positive basis everyone. performance the our constant and during in Thank an speak you, we morning third am reported on revenue basis. Teleflex's momentum with Jake, X.X% on quarter, and pleasure It's the X% to real a continue I a as pleased good business, currency with you growth very as growth delivering again.

by in category. again our in Vascular year, every the of once QX, growth X% XX.X% in improvements in and X.X% top-line driven in Access, This growth Urology, included across growth was performance product Interventional X.X% nearly Interventional half strength Access, the global broad-based, Surgical. first the growth Like during

in particularly was perspective, currency grew EMEA While We within saw we from the and to revenues rebound Asia, growth where X.X% drove revenue achieved performance a XX.X%. where currency-neutral growth we constant improved steady strong currency within geographic where growth a continued Americas X%. constant

other metrics. some to key Turning

revenue was year-over-year In addition to I to our faced able delivering we also see comparable, were with constant operating achieve sequential when difficult adjusted pleased a robust expansion prior-year in margins. the to even and and growth, gross both which currency

gross XXX And, compared of basis during our to XX XX.X%, the prior and increase quarter, year reached was adjusted points which as an points the sequentially. basis margin

basis operating basis an as adjusted XXX While margin of XXX year compared and was points increase our sequentially. which totaled points the prior XX%, to

Thanks additional XX.X% line. margin to earnings a revenue stronger-than-expected coupled per reduced an over quarter represents bottom the XXXX. third during the increase rate, of performance, which to of was with adjusted further and QX Turning tax share $X.XX, benefits our from

earnings as our In QX expected our as revenue per of businesses quarter, prior Urology Access adjusted for we outperformed Vascular Interventional our very Access, When with happy FX, summary, performance grew global during Interventional third and impact XX%. compared approximately normalizing are the share expectations. better to than the

led has constant results, coupled outlook better growth guidance again range our The for product line. and to consideration Access X% Interventional performance range into between between and new than updated Vascular guidance and X.XX%. This our takes a X.X% of from the X% quarter expected to a fourth our us for XXXX full-year strong from year-to-date of with revenue once the increase currency

of However, products, within selected in operations of the arose party relating this issue third Teleflex surgical and issue at is causing suspension that a to largely recently OEM disruption mostly offset This a sterilization an our is businesses. Georgia. by

effective providers issue products. have We access are patients working and diligently healthcare to resolve ensure to to this their

of one the that impacted disruption issue. sterilization UroLift Importantly, Teleflex is is products not product the the by

we as of in which improvement growth revenue constant prior as currency growth revenue increased revenue for our now XX%. called increase expect to guidance full expectation, UroLift range also an our assumes approximately year full-year revenue compared growth, Additionally, XX% UroLift to

reaffirming narrowing from Today, a range and also per full-year adjusted adjusted we share range guidance margin new and as our well $XX.XX are a between XXXX earnings of operating between our guidance $XX.XX $XX.XX. $XX.XX as ranges growth to of and

FX XX%. growth currency-neutral year-over-year and guidance our of reported our updated of growth earnings approximately we mentioned, updated revenue we assuming Our EPS reported Indeed, on a the to well adjusted would into consideration sterilization as last full just adjusted share as EPS issue earnings. basis, per the takes our if I a since midpoint range equate worsening year environment

to more now let's overview, I an of Vascular review revenues The rates noted, XX.X%. in are increase growth segment would was refer the reportable will as begin review revenue Urology, otherwise delivered which I basis. of $XXX.X and QX an that detail. currency a With product Access and our Access constant is with a This unless Americas revenues our million, by on Interventional driven category. of Interventional

million improvement the revenues On business is the access the part call, urology this $XXX.X of represents EMEA, which Access, to it in earnings as was of that Interventional an to of X.X%. of see stated that occurred, in and world increase last and what expected Moving reported our we by Vascular performance our we an led growth EMEA quarter, products. during our the

Zealand. From and in Access strongest as which as compared Vascular compared to perspective, revenues year the geographic is by and standpoint, business our somewhat $XX.X our product increase grew categories, This within XX.X%. Asia, period. while from an prior million, Surgical a growth of a China in offset Turning X% was to New totaled Australia was weakness

reported revenues And lastly, of business increase of X.X%. represents an our which $XX.X million, OEM

said well that on we to is show due to certain OEM growth last the earnings within as orders occurred. of You quarter we business call, flattish may and what difficult that timing expected a comparable recall, our our as

the third did we this during little a better than previously fact, business bit In quarter, expected.

Starting will comments be regarding category. a on reportable and as our strong PICCs in visual my otherwise product to unless was our basis currency as my constant CVCs. quarter me products a comments growth third by Like noted. category Now revenues move Access, global to let in This on regarding driven X.X% sales growth revenues navigation million. increased our discussion Vascular segments, with $XXX.X also of by growth product global well

was catheters, strength based million, on-controls, in broad interventional quarter access, of products. an half the which is growth delivered of balloon closure to and intra-aortic approximately third first $XXX.X QX revenue in the the we during increase Moving X.X%. business the Like complex biologics, year, was in with this results

and of quarter driven tubes, primarily here increase products. revenue Now was million, X.X%. three by Anesthesia, laryngoscope which The an in is endotracheal increase atomization is to $XX.X sales

business, Shifting instruments. X% clips $XX.X increased to driven million sales of our revenue Surgical ligation to by and surgical

robust Interventional to increased Moving revenue a Urology, to million. $XX.X XX.X%

inflated excellent the physician UroLift While of product easier due the comparable urologists progress of to we withdrawal XXXX. the to had XXX adoption year, last continues total voluntary during quarter rate of the somewhat over system, because driving track growth force this make our we on a remain to is new and sales trade

X expected U.S. Transitioning to quarter expect in begin from X, the XXXX. to we UL the with X fourth X conversion UroLift rollout to of continue UL full to base of during a UL physician the the

This segment Revenues businesses here our products, And of review, X.X% finally respiratory since driven the was me category, within let were on other $XX.X consists quarter revenue sales care covered which totaling a respiratory in our in offset increase our bladder our by and for basis, currency down was million. in declines of products. management summarize by sales somewhat our products. constant third of OEM urology an

revenue performance. quarter on three completes comments That my

Next, would some I clinical like awards briefly and to publications UroLift. discuss important concerning

the UroLift August, Association & won the Wells First Zealand System XXXX James of during of Medical New month Technology the Award.

of well across alternative should us New by exhibiting methods as of medical expand yet as excellence as recognizes treat contribute to the the significantly that as and we the the within the improving This quality of to their sector. System life, UroLift patient device market. UroLift and BPH award another superiority achievement example product products innovation to Zealand it outcomes This technical help compared is to try continue adoption to enhancing

the effectiveness benefits seeking noting showcased due BPH. treatment effective for surgical the technologies of Times UroLift Urology medications, men invasive categories September, the shortcomings an imperative of minimally Lastly, to the and option advancement remains during that in for TURP and System, the

recovery That completes complications. UroLift article, patients relief, favorably, the scores low catheterization comments UroLift. with rapid symptom preserved and on sexual reporting In my and function, rates low

me a provide brief product MANTA. are Let about, enthusiastic now update we on another

for For bore large commercially without vascular to those access achieve successful pre-closure, closure. specifically site arterial clinicians help that is reduce reproducible who femoral the MANTA aware, device time may not closure. results helps closure designed It available hemostasis delivering first be biomechanical

this for as TCT, continues there several regarding grow During MANTA, enthusiasm were device. presentations to

account will while in XXXX and Our nice discovery and this market initial been to market U.S. release and the penetration, rates adoption Full a contributor and expect release occur very of on-track; in growth initial rates year, price have our beyond. in in product remain reorder activities to the we be new U.S. MANTA revenue fully the strong. much for January limited

expectations, are led would continues the consecutive I exceed months reiterate full year quarter, Revenue second of guidance our the closing, our and a how to of In performance geographies, growth like year. products our to revenue with driven which both third we and to the pleased nine spectrum increase broad us by during first for quarter.

and quarter year the operating significant as our year-over-year, improvements, continued we per and that to continue narrowing we are sequential, top-line of addition range a and we such, to margin fourth guidance adjusted between In earnings during $XX.XX. share and gross to $XX.XX during expect achieved quarter. And the strength, full

over to the plan. on to like long-range call Tom, turn a I reflect Before, our moment to I'd take

three-year nine currently a are We journey. into months

Our feel to our remain our on-track. and LRP, has in the management for our excellent would abilities expectations their goals I achieve very-much laid and We our focus continued than revenue reaching months teams of our confident margin out in exceeded targets employees to for like nine initial our more May XXXX. ever in first goals. and of their on the thank growth execution

remarks. results detailed a review to full XXXX and the now guidance. completes quarter Tom That I of prepared to like would over financial turn year Tom? financial my third for our call more

Thomas Powell

everyone. Thanks good morning Liam and

Given line. the previous revenue profit the discussion begin Company's performance, the gross at I'll of

increased the Adjusted basis prior $XXX.X versus profit versus in $XXX margin million XXX year all-time high an approximately points quarter, or the of XX.X%. increase quarter, an X.X%. of period, gross prior adjusted was year gross million For reaching the

and in increased $XXX.X increase volumes, the of of a as The was negative prior approximately to primarily compared products impacts adjusted incremental Adjusted these improvement higher margin mix were from favorable programs. tariffs. expansion million XX.X%. margin sales an in $XXX.X million sales or gains gross benefits offsetting from cost reflects year, operating profit Partially

increased period, Adjusted reaching XXX operating also margin all-time the versus year prior basis high. XX%, an points

we've operating realized progressed has robust sequential year adjusted As expansion the of margin.

The XX.X% first quarter was in margin the in now by followed operating the second and third quarter quarter. XX.X%, adjusted XX%

of fourth investment And leverage. further in the margin, is trend of we result timing and expect the upcoming quarter. sequential margin largely operating strengthening expansion of in expansion the gross volume The spending

statement, down this and of interest impact million, our interest $XX.X decrease in cross-currency net quarter. reflects $XX.X to primarily Continuing prior expense the decreased The agreements. the year to income in million the expense compares swap

taxes. to Moving

our the withholding certain negative tax that for reinvested a requirement entity third GAAP a repatriation tax future foreign eliminated non-U. XXX.X% resulting and quarter, earnings. discrete non-permanently the For million on $XXX reflects provide S. of benefit was rate legal the from to of taxes effective restructuring

the as me to XX.X%, in or On third which That prior quarter was adjusted per quarter of as rate our an adjusted share, compared earnings to our year XXXX takes XX.X% year. an XX.X% basis, $X.XX, was third increase to prior compared tax period.

upper-single constant encouraged are strong digit from combined with by growth revenue margin We generation, the currency expansion. stemming earnings

cash select now Turning flow balance sheet to and highlights.

year by During cash was increasing $XXX.X in operations net move The the in enhance nine a impact capital, million on in to payments changes from tactical $XX.X primarily decrease attributable cash in increase from increases by to compared months safety prior the primarily period. flow comparable products. million, first operations XXXX, of inventory stock customer consideration million inventory. of is select levels totaled $XXX.X and flow designed from contingent in part driven The the unfavorable service in working to

reduced times. approximately we in now approximately Turning quarter million $XXX leverage ending outstanding net resulting and to third of by debt leverage, the X.XX during quarter debt

on and notes third issued Company redemption of notes million, notice quarter to Pursuant redeemed XXXX. of comments on the my XXX a principal redemption, price of will X.XX% senior and at XXth a today of in interest, Finally, completes redemption to XXXX due the be results. outstanding unpaid amount holders equal this XXX.XXX% outstanding to accrued the plus notice the November

Now I'll updates. guidance move to XXXX

are nine Given the year, revenue first quarter, revised X.X% our X.XX%. to range fourth currency we and our for a of guidance range growth year performance between expectation a the constant and our X% for between from full of X%, the increasing months and of

conditions, of compared will a to foreign result to headwind point foreign a point expectation exchange year we prevailing As now that XXX-basis full exchange result revenue, previous a our expect headwind. of as in XXX-basis

revenue lowering between As as-reported and range our growth and to such, we a of of are X% X.X%, range from guidance revised between X.XX% X%. a

approximately our are $XX our given and full from fourth guidance for adjusted XXXX reducing rates our previously estimate net Libor versus year the We the million. margin redemption provided in expectations of reaffirming a interest and favorable and notes, operating trend quarter gross to are modest ranges we expense benefit

of adjusted tax prior expectation million. will the the to and XX.X share lower perspective, This XX.X%. on XX.X% full year of of end we fall range is shares being Turning previously be now down approximately From year range. a average anticipate rate to weighted to taxes, expect continue within from full our guidance our to provided XX.XX% a that XX% we count

a a earnings That range are and takes me previous an to raising and range between ranges. basis, our GAAP and and from $X.XX. $XX.XX of range from and quarter third share a a discrete GAAP of of year benefit and earnings range $X.XX our full are $XX.XX, between of basis, $XX.XX. $X.XX, narrowing given to new we per the guidance On per results, tax revised increasing $XX.XX our to between share guidance between On a $X.XX and financial strong we adjusted adjusted

impact foreign our assumption exchange estimated headwind range exchange adjusted a the full-year closure the versus $X.XX from earnings expectation party of of Included foreign facility. previous sterilization in in guidance updated headwind. EPS is EPS included of range adjusted $X.XX $X.XX the guidance a is Also our current stemming a third a

full currency would our year equate range, XXXX If of growth, we approximately our our growth, serves basis, on EPS year-over-year reported of strength which financial to the neutral guidance our mid-point leverage. reinforce a adjusted assuming the to EPS updated XX%

currency earnings estimate the increased In funding despite in are standpoint. acceleration we growth have first pleased very revenue a less the performance with The months based, geographic investment. closing, financial in we is achieved from nine a And and both XXXX. incremental broad product of also favorable environment, a our by

and this And I time, like call my would that to turn the concludes remarks. the At over to prepared back answers. operator for question

Operator

Lewis [Operator you. comes Instructions] with from Thank David Morgan Stanley. Our first question

You your may with proceed question.

David Lewis

for thanks the morning, Good question. taking

just Just – maybe here. two for me

First, a quarter. questions Liam, and LRP you commentary on on fourth maybe, the of a then the couple kind just to Tom, broad

next to well. high a the So, the about got perspective RePlas delivering guidance Liam, look as think the you got here, year, you've X% LRP you to some of kind was offered, you've are point above end X% of Manta, and closer I range X%,

year, to next little XXXX, or think deliver have launches follow-ups I couple to about you X% do the better? Liam, Tom. X% you're going for those the LRP about can right think I for product as around And is of I'm a to given sorry, So, way a

Liam Kelly

Sure David. Yes.

we So couldn't based our earnings we with get on be said will prepared we're I February, remarks obviously, XXXX in we the the on LRP, the guidance as the but progress comment, will LRP, in my report I when happier making. QX

in within months year, of months but incredibly revenue growth nine has only our are the We solid. first nine been the

take we've guidance year. So, revenue been months, within grown twice the nine our X.X% to year-to-date we've and through up at able the

the and into UroLift really guidance. wasn't previous play XXXX in got, our will also Japan we'll feel in in in we that XXXX, come confident. we Manta We've obviously have So

in the revenue the community in this on margin that line, showing LRP, extremely able out So quarter, hit product, do all-time we've in continue just company the regarding XXXX feel that May the through able we significant force our the at our where and some our of confident for we we've of income line margin margin to in businesses, time, external the in to that high time the the same sales for demonstrate not we've statement, gone also to the high behind the invest been as an continue as we leverage op for expansion and company and QX. goals particular set year, invest to UroLift point the to the gross there in being we all an in while revenue it's will

David Lewis

Okay, Tom into conservative the very for finish And strong? number moving then tax, a there's guidance interest, a us of the it looks drive the and a drives just that sort I of you acceleration just that fourth implied looks on bit confidence little of and conservative? like about if fourth quarter, in for bridge with point first Thanks positive sterilization on the quarter could on improvement. tailwinds Liam, earnings the two or the just wonder guide what as negative year it the reconciliation, a you, or lot the implies us two sort and components pieces helpful a said, momentum little fourth help because so into you Could margin much. earnings, to just growth quarter, between

Liam Kelly

will I'll So, the to Dave, the cover cover EPS get we Tom and revenue.

first so on So, the all, of impact the issues. the you of side, revenue have stabilization

quarter and is of revenue. our all, sterilization in the that to in will it's our an the think in cover and let it million, have going fourth in contemplated contemplated in impact. guidance is updated just guidance about updated raise our it Tom me the capacity do of our saying start impact We EPS issue, by with First contemplated $X.X contemplated and

a headwinds XX his he is issue. full about But about $X.XX, on that based points in basis remarks year said sterilization that's prepared as

on quarter. your obviously, Regarding question, and we have fourth billing an in the David, headwinds extra tailwinds, day

from it issue So I is think billing pretty in much look washed fourth quarter. the the is impact at day sterilization the way the the you should with

up I it at to of Now take quarter, to and of to updated feel get and in guidance midpoint set the mid-sevens rate growth a if forward top tough – the the we the our that was What midpoint that. grow X% year. against really a the for X.X% that to of we against order the this in a prior the in on in fourth about were we on comp year, prior our imply up we're that you the planning put – able like guidance in Teleflex quarter, the range to are do our the we able guidance growth in midpoint confident is again And would and tough comp. forma mid-sevens if really in a X.X% on pro also grow the that's of QX

the and EPS can really the tailwinds, Tom FX either address I'll are So way, let those now headwinds question. go and

Thomas Powell

Sure.

look if XX% our we're EPS, So we guidance, midpoint say quarter that at EPS at looking to of given growth. I'd our XX% fourth the

So, quarter. solid very another we put look up to

the quarter an $X.XX, in at performance, versus of came terms our favorable third outcome, we Now raised $X.XXX. internal as just by and versus by the in midpoint, we expectations, consensus guidance favorable our

associated closure guidance facility. of we've from the $X.XXX Now foreign from range, exchange also in and stronger headwind addition the a to sterilization with adverse included impact in $X.XX a $X.XX that guidance our

But are pretty XX% a look performance got we overall, of in excited we the mentioned, year, we've impacting XX% strength us growth we finish we're range. kind fourth So about into the earnings to as as of are items the the of negatively. couple as expecting out quarter, that

Liam Kelly

on And said. from Tom comment wanted Dave, that just I what one add to

year. in UroLift come those in hit new are had actually bit than little additional running We ground headcount we're anticipating QX, to we heavier we in anticipated. anticipated would DTC that quarter, a doing behind the sales in And QX, We we're fourth hires had QX also in also in going some investing of additional so next that QX. the bring

I again, – our up really is about what able call what like setup earnings. are I to we the So

the call which sterilization guys business the up and the to offset guidance, earnings bad growth We our invest some behind are drivers is. able in

all, would performance our that. So of nine be in I months the business with think all first guidance the reflect couldn't and we happier for the

David Lewis

right, clarity thanks Great All quarter. for the guys.

Liam Kelly

David. Thanks,

Thomas Powell

David. Thanks,

Operator

Thank you.

James. Our next Larry Keusch comes Raymond from question from

You question. with may proceed your

Larry Keusch

a moving Perfect. and UroLift the Good then obviously to sort procedures set the phase focused Liam, of you outpacing again that's and and as have be sure you we're product year for through for morning, where into this how making the strong gain and physician really of continues on the force and expectations fast how trending kind is talk the this bit Liam, little everyone. one per sales you're average followers, traction? thinking One to is perhaps Tom. about into that continues maybe really, could on

Liam Kelly

we UroLift, growing Thanks, had months XX%. for through XX.X%, of resounding first at Larry. around the at nine it's quarter grew a the it And year,

in you're easier that, quarter the So year. we slightly exceeding right, voluntary of a all of our the had the product product third This last expectations. had comp internal withdrawal QX is because

definitely that quarter a incredibly making this that but notwithstanding So on focused of product we're standard has this care. helped

physicians, procedures the the The stable. physician a continues business is four to average do Regarding month. about incredibly

care. the champions We product make we to continue to continue develop standard and this of

having sales and the drive helps about number performance. obvious DTC up will think publications accelerated help, wakes product think is one a an to everyday of continue force as we and I I only obviously advantage the thinks that Larry

phase second clinician has the moving in we for if very we And been XXX are is so, follower. not, fast from the achieve, adopter right exceed me have has of not year follower, modestly we move particular train the as I targeted will this to into the now said think I move prepared definitely we in that to as remarks, to encouraging as what growth slowed clinicians my early we the and and fast that

very data using now broad real to Teleflex little clinician appears always bit aligned data and think that here all the has clinical thought They strong paid I is clinical very to require are require that to really it board, four take that those need they Larry. right ticked they requires, fast get Our for the a that clinician and they're going to world bring of moving procedure will follower, be sit on the we to will ensure to boxes data. been for product, the coverage as longer there that

Larry Keusch

Okay, is to when your perfect. Liam. just helpful, of from of think that, be the lastly, they temperature might are expansion, sterilization provider to wanted headwind, That what we not are want I think issues? was of here I for guess, just margin that sterilization And, getting about the XXXX margin feedback gating what of in do LRP? sort expansion so LRP, through then, a XXXX, on And operating question we you as your how given these your calibrating of your actually And resolve to they that on kind take kind some to bit and how about guess, for the in for the confidence just is gets you XXXX that there? think able

Liam Kelly

Okay.

So take let Larry. me it in chunks,

with our me LRP. saying, cadence in Let ever I the more expansion margin said as prepared than in within remarks, our and margin me let of in by our and begin confident LRP, start I'm our

while and to I and margin from come operating all-time said, where in XX% an it our is going high Vidacare. our we're about both and Urology, business to hit growing As where our we the all Access, philosophy growth is of come from, And mix, going that particular PICCs Asia on is Interventional Vascular margin. is and businesses Interventional in equal within in Teleflex not growth

All for it are if those of nine businesses of at LRP, those exceptionally businesses performing margins, the a our has look you our performance. and OEM, can months those which well goes and the and great behind add-in accretive the goes, you are had where Larry, are see to then investment that first

but than in to to can expect Larry, the – you I Larry. we've would we what regard confidence, that cadence, that as I XXXX in XXXX. guidance would would want With on see to I our what margin seen get question answers more the don't your so and expect, expansion appreciate, cadence into is With XXXX regard

expect but XXXX So XXXX, margin expansion expansion then would that both in uptick be rest XXXX, assured, to to and further and margin XXXX, our years there uptick would you would in see in be another our in expectation. an

partner the re-qualify onto in question the that working and on we to when much reactivated. to They weeks area, your other Larry to to of have clear been in may issue began of has to Atlanta sterilization sterilization, when begin our cycles then with areas other very ago, do us this as arose number help line And a be don't facility us that. sight

I think working that are county they with the officials.

I think have we that of that the with line think now but they they and, are sight. are EPA working I right don't

marketplace to at will we is time. revalidated that the other supply one expectation into envisage Our have quarter cycles would product us that allow continue would to by and we that that

U.S., all accounting been And devices. think they helpful sold oxide, are the FDA available with readily put XX think medical ethylene Larry, there come that that note is as facilities process at said, than also our note it's you're $X devices plastic so important last that has a can alternative almost FDA serve the billion week have out some of products. dealing billion half statements what to that for sterilized stating I especially no when I a with viable and is more in the that of And out in

authorities educate with So, local I government Air issue, could of on what I particular, work the AdvaMed and importance having to to was Act. our product the are it sterile which ETO these because can continue see risk incredibly to in in and Clean helpful have them the MDMA think the marketplace a that much associations, from bigger than also very complying environmental patient

Lawrence Keusch

answers perfect. Appreciate for very earlier. the Okay, Thanks it. detailed

Thomas Powell

look XXXX just the that we just on I incredibly well. at margin – add as that, And expansion, is performing believe we business Larry, to to

business the creating is So financial Absolutely. leverage?

is are headwind XX-basis there result year, and about However, of another FX, XX are that printed kind margin tariffs that's limit expansion of points. kind on in point been three a basis factors those the the

And the but Japan the and benefit then, UroLift, longer the MANTA, investments the UroLift got number hires acceleration this market in believe us no sales a fourth expense include we made we've will we've development those got term, which in year, through the real benefit U.S. an we've for of pre-launch now. from investment quarter for future, of with the

that's so points. XX basis another And

about So, away this believe XXX year if think go got impacting provide kind benefit are in the future of that that factors about or will the points you for it, perhaps we’ve we future. basis

solid the year tariffs very business So, by to FX of we've performance masked is the the and underlying being somewhat this make. chosen of operating investments some

Lawrence Keusch

for Thanks that Great. color.

Thomas Powell

Yes.

Operator

Thank you.

comes from Richard SVB with question next Leerink. Newitter Our

You may question. proceed your with

Richard Newitter

have Hi, the I on and thanks. quarter. congrats two,

sterilization, impact a us question, on I a as should I sense expenses first for I of color impacting first some things my it's XXXX? pretty in this we give mean, could in how the big Thanks but know $X.XX time. do the that's – year, is take earlier, think a half placeholder to you for or carry next or First impact, XXXX, these ask, as to dialing into is just an over quantify impact what a expectation to we your want be about

Liam Kelly

with another we relation working to another a expense in expect size. What in either wouldn't sterilization are material validate Rich, in our is or So, XXXX partner to I cycle in this. another geography doing

would would a million, an you $X.X if than anticipate wouldn't $X.XX is of quite little I a The expect $X.XX impact frankly, Rich, bit expect I I normally. to less So normally $X.XX get significant uptake.

to And the validated minimize margin Because been in having impact. the well in in the that cycles products category have working gets down I obviously, we substitute the in that products order other as EPS the particular comment, said to profile earlier in of what it impact, And minimize as that's helps my anticipate to early XXXX. us we $X.XX. of being

So, and working that. towards we are

Richard Newitter

Okay, year next XXXX expansion points thanks. And, something that, what margin between It's in saw achieving XXXX, consensus but for what XXXX XXXX to maybe to Liam, then expansion plan. out versus of for expansion margin to then in I plan. cadence see in long-range more could, kind range and the if I the XXX XXXX. And of margin get more just just your is over versus XXX basis in range baked the XXX long throw we of what appreciate you'll implicitly north of it's the in anticipated

you be guess, cadence to okay you a color, that framework just for is the I Street could street, as where comfortable thinking the about the an feel place give do generally Thanks. for directional with is? current

Liam Kelly

Thanks, Rich.

can't As comment stage. XXXX guidance on this I you probably can appreciate, at

pick we're would line margin let up frame So, and said, to to it, I expect to hope XX% XXXX margin to XX% and think on at what very in confident margin. expect in a me give with and I'm some There will I XXXX that look to here. you for would I I is to be you're XX% and be as flavor. QX getting XXXX than what a more we're pickup Rich, help that I I in appreciate. – I by to it's op on me XXXX XXXX, you but until said. expansion hard our gross comment XX% try and help will very there op guidance, get But you XXXX XXXX. that on to expansion margin maybe going reiterate further you by confident will we in sure in getting

Thomas Powell

we've there they up step they in more throw of happening why steps out than hear couple in to much just got And so or XXXX, a up factors why that XXXX.

drive amount in the more XXXX. pretty our by will have we of of Then, to conversion also to footprint of meaningfully cadence the UroLift X expansion. on will XXXX, XXXX than actually projects, just we the going significant we complete is savings in expect that's First a and margin

up to are drive that serve two XXXX that years. really than the other more margin expansion, those factors So

Richard Newitter

lot. a thanks Okay,

Thomas Powell

the Obviously, in some reduction put year that of helps the this we XXXX. investments in

Liam Kelly

Thanks, Rich.

Operator

Thank you.

next Wells Fargo. Our Shagun with comes question from Singh

with proceed may question. You your

Shagun Singh

a you Hey, questions, much and great congratulations guys. for quarter. Thank the taking so on

Liam Kelly

Thank you, Shagun.

Shagun Singh

that about And to is to these in the reasonable? And core UroLift ex-UroLift XXXX? should is bps tracking we also and to about then X.X% then to two X.X% year-to-date I about tracking is a buckets and of demand, you LRP, is expecting you be then on us Street Liam, MANTA, top which pent-up appears about on is give if modeling Are XX to XXX think X.X%. core can your take XXXX? the contribution UroLift How have – follow-up. from tracking

Liam Kelly

latter – your first. Yes, your let me deal question point the half of so with

if midpoint X.XXX%. guidance, take So is the updated our you it of about

of – the that X% Our rest around is ex expectation – add and will around X% that X%. around UroLift will add the business will pardon, add

that will of midpoint at the get that our So to X.XXX% us range.

we That to the progress a very make continue testing very the and We're as I regards me feedback got my high with prepared remarks, address your rate from we've sites. U.S. positive. said getting a quarter. with excellent real to is LMR in To the reorder in positive MANTA, to question

LMR QX. we the can as strategy X, January our and we you, I pretty full on finalized will are pricing continue tell will here release go I We to on sit with much And XXXX. today, in market

when your XXXX, to we for its to again that obviously to and comes can to but be many like data. quarter can't our gone Shagun all the expectations start it you, announce revenue our guidance to and but for will give back better on I tell again regard colleagues, With and year, outcomes I patient XXXX. my positive, in impact that of the clinical results comments do four guidance it's expected unfortunately, I than

of the showing This important vascular really to they surety from and every that time. data down know and that XX the XX product to in reduction robust clinical hemostasis major to seconds discovering to complications is time, close is going has they’ll XX% it we're X sites first what meantime closure minutes,

in And very will it positive. going driver be it's well. XXXX. a It's So

Shagun Singh

UroLift the you color. reimbursement so to is on follow-up. commercialize April in for Thank effective, launch Japan reimbursement, much how as you're likely preparing for you which once to where much. are so that X? wanted able you on quickly then becomes you And XXXX Thank – waiting are are how you I focus a for and just in

Liam Kelly

of in so reimbursement to expect and the to latter XXXX XXXX. we yes, half we So, expect be in generating revenue

are specialists the and urologists need during assisting in of correct development generate for that, opinion the are the will marketplace So until with process, of with working ground, that have preparation product. they communicating revenue half in is this forward and absolutely authorities XXXX. you're they the this key market the And that of the XXXX and product reimbursement doing get in that are What continue XXXX, latter on that XXXX in the into leaders order of we we the part that in is there. the investments we pulled and an aware got we ongoing to was ensure and in

having And again we for LRP in because we Shagun expect. in I UroLift which now Japan XXXX, initially revenue that didn't reiterate would approval our the in anticipate was not

which plan. So, wasn't our we do expect revenue XXXX, original in in

Shagun Singh

Thank you.

Liam Kelly

Thank you very much.

Operator

you. Thank

Our comes with UBS. from Taylor question Matt next

with may proceed question. You your

Matt Taylor

happening thanks hoping the treated all treatments are is expanding seeing environment, you on with of us might patients and Maybe any also competitive dropout is some surgery? Hi, dynamics. comment patients. for you And on the MIS those other actually that into view have or TAM the on if color other comment be seeing you you whether mostly can just pickup what's on Are the here? changing taking give question. UroLift was I you patients drug still

Liam Kelly

Yes.

surgical don't the from that is that if category. take our expect showed So our and U.S. we regard you patients changed. too the I they much and the see And the where the dropout doctors that best as UroLift believe which majority surgery. at to TURP because we patients of study L.I.F.T. No, has promote as had or drop of data from had almost a XX% the product has have category. UroLift move draw With had we changed also come wouldn't TAM, $X more came the and off dropout do market, that We a during The market believe all, anecdotally, more in from. procedures? patients into a still drug billion think we patients don't a traditionally treatment drug we will that's would product, for was BPH with the

of has pool also prostate, because in X% cases But prostate disease be examine the bladder an patient, they adding got find will for patient the those we're patients to a that they ongoing pool. too as added is they and of to patients UroLift surgical may have large the or that may the of

we goes draw surgical TURPs are expected to the therefore go as off adding So, surgical as we've also never we would up. down the example UroLift that pool, so pool, from for

steam haven't technologies is see we of more ones, there with any I technology on form TURP with just that third seen less the new and of a your traditional to ablation. The rather landscape, the part we Matt, question, come was think or the the than different are competitive done marketplace out a

period the on than invasive won't dysfunction, in in data the some to immediate sexual gives compelling that you is on risk world data so that at you for for could rather outcomes, time. and because a continue of And catheter to are focus a on we still have world opt patient on the as a real is we you catheter a believe a Friday, your procedure compared real is can sitting clinical relief patient other And world and procedure that real data a surgical Monday because believe than no any real placement on morning sexual guarantees procedure that that dysfunction, wearing a technologies, I of data, instances be compared there the our the better almost will we've the catheter, with an world to technology done, back data. worse they desk whereas other results wear clinical results the out UroLift seen showing in go

Matt Taylor

what of market had color. follow-up, do reimbursement That's could there? out one in at is, years like addressable the which the a look you I China, just couple looking Thanks think probably good Liam.

Liam Kelly

the plate. we have in China that is very advantage the urologist. Matt, China point give that as the sizing enter we working China Chinese market as call as is details that do population an more space. a to insofar be standpoint, some So, think – and we I on have robust And market are in in from currently market Chinese into reimbursement able significant the we we'll that market, world a a paper

every but has is always this an and procedure. has out-of-pocket person an for not been, just it's it procedure, for So the that procedure experience out-of-pocket for the

stage require in building if the of we push a and get that to are registration if would Chinese dossier don't would Matt. they XXXX, do, XXXX, product to at sometime – our reimbursement, the would will We clinical late anticipate into in we of submission the this they authorities for position study, be that

Matt Taylor

Okay, great. Thank you.

Operator

you. Thank

next Denhoy question Raj with from comes Our Jefferies.

You may question. with proceed your

Anthony Petrone

for we're just Congratulations And proving is be actually you trending market can The on in Hey, quarter. then TAVR the the on just is low looking expensive this this to Raj. market, on On the you're with risk technology indication. looking one think I there year, the couple I obviously, how M&A. and at balance more recap maybe procedures. also Anthony the a MANTA, and now at MANTA, is is have sheet using EVARs. XX,XXX

what out your versus And so in the two-end think How do markets? you have are the seeing a how used those I'll in release, competitor? are then limited market seeing follow-up. shake pricing be Thanks. penetration ultimately, then can And these you MANTA being in you markets? two-end And

Liam Kelly

in let me before the market the size that in to it's seeing probably is TAVR. we're expansion We What million $XX the is million in $XXX in of to could the market add procedures, limited, potentially. the procedures size so first as seeing we're release into another market. majority being the that used that million lower $XX what or So the TAVR million is limited $XXX our all, TAM of

it on centers growing intervention EVARs – does are as TAVR, larger, focused because but are they does faster well. the TAVR it if and the are the it and We obviously is has, that they

centers a a centers. So the used with got number the obviously, now versus procedures pricing smaller being and cases. we're the Impella price the in From of perspective, relationship and a of much have also volume bigger up better picking even it's understanding we EVAR for between

for product volume. strategy our in launch pricing nailed be ensure to have adoption we to down much pretty that complete pricing in won't of the have a based X order on barrier We confident preparation we pricing and full that January feel

on call into competitors listen go You'll Anthony, I the our if as have to don't excuse details anyone the same sure the me, else. to pricing, I'm

tell lower to be share at competitive that to but in pricing barrier you, want adoption. the And And that a strategy. So, it the gross is the from I will an that even end we for this that over for have I Teleflex a pricing of driver be not product and still long-term. up, accretive will to we believe to reasons, feel can incredibly confident our Anthony, it don't volume, accretive strategy significant growth and product we Teleflex margin a

Anthony Petrone

actually intra-aortic follow-up pumps. balloon instead enough. And of be, will Fair actually M&A the

benefited Thanks quarter, So so competitor congratulations. looks Teleflex update like at dynamic playing was your pumps over business the just again the from a had that It recall is case that and last that. this how quarter, seems that and balloon it on out? an intra-aortic

Liam Kelly

you thank Yes, much. very

to a do intra-aortic balloon see the Anthony, won't pump customers recall it's to fairness, purchase benefit of period by capital competitor, postpone tend equipment, time. they’ll a the for the what because will we in that, all So

taking Our is to down growth from that competitor. share purely same

in benefit get in that our growth rate by a would on, you balloon there, business hangs competitor longer then. share Now, the goes very, recall pump very But area. us QX, growing out driven will you the is still the that our expect teens has if but been and won't, we that taking in high from

you that well doing I business. market, new our in happy we with pump very are with we're the confident on that very exceptionally we're share business. and taking So it's will tell

the longer are will on We into goes in as get it we and the recall, we quarter benefit, now the the coming – into believe particular in and see see of this I quarters. start to

Anthony Petrone

Thanks again.

Liam Kelly

Thanks, Anthony.

Operator

Thank you.

question with Weinstein Blair. William comes Brian next from Our

your You may proceed with question.

Brian Weinstein

thanks Hey the good. guys, questions. The Americas or very the was obviously numbers for U.S. taking number

and to about maybe going than flu-related And, distribution about at any may or get in then in you to channel. hearing the somewhere you though get in little season. pulled seen bigger usual get patterns, products particular, back are think bit Question where a we that seeing have into need We that forward. suggests we're bump up things the anything is hit sometimes have past, the by distribution heading overstocking ramped seeing a

of So any about saw Thanks. you in impact that? any can you talk that

Liam Kelly

it. think Absolutely, Brian, looking are that at we I

First saw a of all, the quarter. we distributors third by modest destocking within

So, key the more I for but the normally with to you distributor. expectation, sell I in the is encouraging that's in into revenue me, market line American our and that, North is see expect revenue recognize the

the customer end look demand, But is at and my greater through the at I tracings I'm actually I selling look customer than recognizing if in distributors. and my what if demand end

there Brian, gives about, be particular, me issue modest regard to certain is that Having that quarter. have this. I I the that visibility I've third since is a one of an level think the should I stocking destocking into confidence against in it, with us best that has it's, the portfolio the don't worried built, protected that seen in not So we've said but

gone quarter our other and every we that that In got fifth of on when that tell it. execution revenue, absolutely portfolio back earnings. to is had and happened to been some these say build is hardly community deliver the have have distributors, of moment happiest level on the and have feel statement; we bit the is line I the have we're type whereas the that noticed that's that the delivery in in past, me, our trying restocking I margins in and And investment through half in the of has even QX our to trying was Teleflex, I almost and in this destocking Teleflex our income business consistent back got would to third to we're that's box-moving a now QX for only you of business and

at the So there high a very level. our level is out teams performance by of

Brian Weinstein

the Great, thanks for question taking guys.

Liam Kelly

Sure, Brian.

Operator

you. Thank

Our O'Brien Piper with Matthew next Jaffray. question comes from

proceed with question. your may You

Adam Maeder

and for the for Matt, Adam questions. on taking quarter congrats it's thanks Hi, the on

Liam Kelly

Thank you.

Adam Maeder

assets about to speak just including or the for months this multiples the next attractive I follow-up. are company seeing wanted ask a capital I potential And M&A, for at or allocation the XX still so over you point? to had

Liam Kelly

Okay, Adam.

leverage. all, of let start first our So, with me

this leverage Our of X.XXx end at the about quarter. is

not on us the seeing traditionally for assets we never Teleflex high quality we I'm there, been that has issue in the assets, come in have that were interested in. Multiples out what the expansion, have capacity. definitely assets focused we have least look the had lower at, were quality So assets The assets. always which been multiple at

of is CEO. easiest in my than assets. at preferred capital on I'm the to of guess, Our to active M&A I I to we in in looking continue time tell and marketplace more over do use time of you, any M&A I as number spending way took the the since very are have last months

to see attractive the pretty continue and that an we're in looking space We broadly. look think us what advantage we area in gives I this that is assets

we're OEM course we're never in area. looking the looking we're health, in looking in the men's looking Emergency We're Anesthesia surgical area. in looking So, area, Medicine vascular looking and we're Cardiology, area, and the in Radiology the stop vascular area, we in Interventional, and of area,

at, that we we'd we look assets the and able spectrum but environment, rest broad to we current assured a even value and active be out think at looking in we're So are busy. carve the

Adam Maeder

update Thanks. Thanks then more space, that limited that's us the been should you and squeeze to in on progress for the to I a feedback on of the know taking launch? rollout That's expect Percuvance, very talk we questions. more clinical in can And the side. launch full clinicians surgical when from clear. you one about Can if can I just a

Liam Kelly

Adam. thanks, Yes,

launch. the market continuing with limited we're So

to a product. launch. is said Percuvance times, couple the me I a As limited show really finish want of We

get We before give get update. have once well further about the we some assured, we'll clinical XXXX guidance, work that rest excited but a we want to we to finish too as product,

Adam Maeder

you. Thank it. Appreciate

Liam Kelly

Thank you.

Operator

Thank you.

with Our comes next Securities. Turkaly Dave question JMP from

proceed your question. with may You

Dave Turkaly

great, Hey, thanks.

did but apologize closing? plant, did, if or of it you have may was going mentioned cause that You this, the occur sterilization exactly when that I and what offline

Liam Kelly

Yes.

documented local working to the was last it became, pretty all So initial the I the company standards and now they with well the to are an saw Atlanta The in in facility. County the a The emissions issue within notice Cobb Dave, environmental regard the company relative were that with permits. Cobb put concerns Cobb for this the County the area. out I had believe, the working is local been relation trying to ETO media. Then with County, compliant to reopen has group,

have sight of will EPS. to the have any facility, to in they As and transitioned I revenue reopen minimize but to $X.XX qualified line when cycles be to don't impact $X.X able said products other in down the earlier, million they to we as that sterilization

Dave Turkaly

something $XXX Got about one-time, it, we thanks. one, benefit, or think is last a tax the just said but like shouldn’t million the that, And things then I that sort of is there quickly again? restructuring, I'm for sure but other that that, O-U.S., something expect opportunities see it's is to are just you

Liam Kelly

future. is count may a will quarter this in that on other only. quarter, restructurings the benefit. a occur could similar on bring benefit That one-time out there that that I some be wouldn't this in There

However, those along I anything right else now wouldn't of doing lines. no that. sight count line is on There currently

Dave Turkaly

thanks. Great,

Operator

Thank you.

with Needham next Company. comes Mike question from Our Matson &

question. with your You may proceed

Mike Matson

thanks. Yes,

possible? exposed. just a not current to perspective, mitigation to facilities the problems with with do So issue, prevent there is you're products try type future that back you anything just other impact the from in address other that risk and this understand is the of just products the I sterilization or But to are to could trying

Liam Kelly

comparable inventory our risk on risk have we is other sterilization discussion of around in we issues. And Mike, part one against have that in tactical at major also inventory, additional in Good done his codes, stance. in have around mentioned we our thing mitigation the Tom a increase is mitigation as cycles, validated question, cycles any increase looked

the I sterilization crevices, States comes certain of requirement there billion it a And devices products in using work the types with that back do sterilized think, fact on of other made processes United really not are it because that Mike, are ETO. materials. medical deep XX products is to

to a would to we environment environment, want as a approach got protect the in, we've think in you're all here. I because to Obviously, of LA, than in want any have other pollution but have balanced if we living safe So, exposure much you have all area. you to live

FDA statement I to common that week. and the is I think, my by was starting made last particularly It prevail. is So, they observation sense encouraged

Mike Matson

just get VAC SAFE committees? MANTA and that help adoption part there Thanks. any thing then trial And drive maybe thanks. MANTA, economic any any trials through underway of data this anything economic on just Okay, as or to other one – collect data the follow-up, or could is is efforts

Liam Kelly

Yes, study it is a That JAMA done study XXXX. $XX,XXX area published XX% from X%. believe treat. the to in data stated would for over was this compelling a product that reduction X.X% is there in was shows And major those in complication that hospital clinical to I major cost that where complications the a

compelling you if argument that study, with any VAC the JAMA Mike, that for So, committee. combine would a that be

Mike Matson

Thank you.

Operator

Thank you.

question next from KeyBanc. Our with comes Matthew Mishan

You may with proceed your question.

Matthew Mishan

cash LRP. update me year I where and there to you of are free sure But for free $XXX annual today Great. throughout And in, guys LRP And flow your think cash increases one. I'm million year? and flow was thank you $XXX the for the are squeezing Can seems between you supposed I expectations some just have per bridge those? to there between those you delta and somewhere expectations? that be through be million kind a Can

Thomas Powell

Sure.

and together to would $XXX cash to guidance had guided So assumption and free fact to the the LRP would build XXXX cash point. that that said that average and million put XXXX between $XXX Day, your million in inherent we your Analyst in the when period over free flow point was flow at we

of less XXXX three-year kind excess. well and XXXX XXXX, that it in than we in be thought in would line, average, So

and at experienced have business decisions we've the of aimed an these we've operations other improving LRP on made the business from putting decisions together, near-term impact since flow. will Now the and improving results some our free NeoTract cash

I'd million. cash million approximately So $XXX from for XXXX, operations and around now $XXX flow expect CapEx of

same we're Now not give some flow of initially the out key LRP expected. we let the deltas me level why there, we seeing you at put cash the free kind when from that

actually is contingent as result, a performing and of in of consideration go we excess are through contemplated paying flow NeoTract initially from higher cash payments was is and booked level what was additional than better purchase a The that those what first originally in accounting operations.

restructuring Then, XXXX. XXXX savings there's service, reevaluated and balances as And have generate doesn't And in our cash until another associated enhance also in increased effort program safety we've the taken in CapEx program and outflows really XXXX. addition, have levels stock in in then to action result we've an And with inventory we we customer strategic a additional put in this it. year. an we that our that there's that also invest to project in

the the previous we're free part the customer help but restructuring the we well as company on-time actually think but will And Now term. in seeing of that expectations, us the results is term, including the will improved cash pretty why from increased benefit these that help we again of longer programs the delivery. over have We served each will this we're business believe our service flow the inventory improved think as happy longer over-performing. to ultimately NeoTract reduce is reason

Matthew Mishan

that's is or that that XXXX XXXX as follow-up is contingent well? something a would that and a just And that in impact consideration, else XXXX Tom, one-time changes is potentially contingent to – impacting payment the

Thomas Powell

It could XXXX. potentially impact XXXX –

Liam Kelly

XXXX.

XXXX in it NeoTract. runs the is and bulk to consideration through of of the end So XXXX the paid for contingent

Matthew Mishan

thank you right, guys. All

Liam Kelly

you. Thank

Operator

Thank you.

Stewart with comes Our Barclays. Kristen question from next

You question. may proceed with your

Kristen Stewart

quarter Happy great Halloween. a and on congrats guys, Hey

Thomas Powell

Thanks, Kristen.

Liam Kelly

you, Thank Kristen.

Kristen Stewart

Just follow-ups a me. couple for of

circle an And out still something that understanding the figure follow-up didn't Just wanted in RePlas, a something on, trying first which on question. expect on to filing as miss to Is you're that called on update that, I sure just want to mentioned then an back on is timeline as I now guess, update that guess that as well. product there could was something I to my was being He provide have you that. EZPlas make had David's I that? XXXX. I

Liam Kelly

absolutely. Yes,

but I to about think David EZPlas. asked MANTA discuss happy

to submission. tell last our our excited we the we're positive as on of continues But can line that constructive very a a said once know all and it to about BLA can I military, the the would had clear the collaboration obviously we with FDA, As on and humanity. call, an have give you FDA be product we update Teleflex, we sight impact

done have submitted significant continue this we FDA. we journey, As of and testing that to the we amount a

for We positive Again, forward. pediatric we will continue a big that months. agreed I next which plan, few that the think study have step we have the ongoing that we working the testing FDA, with development. a was is doing are for us And

So glove clear we've we working are clear covered as making have the line soon and and are as timeline submitted unchartered FDA, with to sailing and update of sight hand we BLA, done, the but waters the for that of community. to will FDA, testing them, progress, with a and being we course, the investment we the obstacle a

market. market is $XX you just about we the had million in remind believe it $XX military by XXXX. that million opportunity, and $XXX we would this I product civilian $X million And for million our LRP in the that in

and So work making on continue to it progress.

Kristen Stewart

Perfect.

sure what's is the I UroLift have you or believe fires all about just then you safety kind too, level? alternative rolling as anything, going with that guys if just guys blackouts have some that question is manufacturing. California generators the I sure in just level to you I wondering in I'm the am on of have how Pleasanton, everything Mexico any there. else, thinking of on stock with probably not think guys in manufacturing risk anything any produce and or So, by you risk other of that about a there, impacted are at guys but

Liam Kelly

wheel, We on Kristen… hamster have a

Kristen Stewart

hear. to good That's

Liam Kelly

we… actually, are We

Kristen Stewart

thank Perfect, you.

Liam Kelly

power of. in outs of bought months, haven't of we the XX sites any manufacture dual in this impact we as our NeoTract can risk. a we identified opened I'm we first shape and in product there. existing the this one When company, We're aware good manufacturing facilities, so in had the that And alternative an up we site

and the already as manufacturing impact no power So, a outs company. dual of established

Kristen Stewart

hamsters Glad Those to then. well doing Perfect. are hear.

Liam Kelly

around circles. They're going in

Kristen Stewart

Congrats guys. All right. the that quarter. feel All thanks right, very like much on again I too, so.

Liam Kelly

Thank you.

Operator

showing Elguicze call not the this any any over turn back to I'm for further like you. Jake would I questions to remarks. at Thank time, further now

Jake Elguicze

the and call. call the Thanks, conference Incorporated operator earnings today. XXXX Teleflex quarter This for everyone joining us concludes on third thanks

Operator

and Thank Ladies gentlemen, call. conference Thank you. this concludes today’s you for participating.

now disconnect. You may

Teleflex (TFX) 31 Oct 192019 Q3 Earnings call transcript